(Q53856522)

English

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. (English)

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

0 references

1 reference

based on heuristic

inferred from title

endometrial carcinoma

1 reference

based on heuristic

inferred from title

author name string

Stefania Bellone

1

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Katherine Watts

2

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Stefania Cane'

3

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Michela Palmieri

4

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Martin J Cannon

5

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Alexander Burnett

6

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Juan J Roman

7

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Sergio Pecorelli

8

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Alessandro D Santin

9

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Gynecologic Oncology

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

98

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

1

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

92-98

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Two pathogenetic types of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Current treatment options for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Endometrial papillary serous carcinoma: patterns of spread and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Uterine papillary serous carcinoma: patterns of metastatic spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Interleukin 6 and its receptor: ten years later

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Establishment of human endometrial cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Virulence of papillary endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

What staging surgery should be performed on patients with uterine papillary serous carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Dendritic cells as adjuvants for immune-mediated resistance to tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

IL-6 switches the differentiation of monocytes from dendritic cells to macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.016

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.03.016

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

1 reference

Europe PubMed Central

21 May 2018

http://europepmc.org/abstract/MED/15904949

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53856522&oldid=1774230453"